Arcadia Biosciences, INC Form 4 insider transactions

Arcadia Biosciences announced the termination of its proposed business combination with Roosevelt Resources, prompting a renewed search for strategic alternatives.

Arcadia Biosciences reported an 11% increase in second-quarter 2025 revenues, primarily driven by Zola coconut water sales, but recorded a significant net loss due to a $4.5 million credit loss on a note receivable and the absence of prior year gains.

Chief Financial Officer of Arcadia Biosciences, Mark Kawakami, reports the acquisition of stock options.

Arcadia Biosciences CEO Thomas J. Schaefer reports the acquisition of stock options.

Arcadia Biosciences announces a 22% increase in revenue for Q1 2025, fueled by a 90% surge in Zola coconut water sales, alongside strategic moves to streamline operations and advance its merger with Roosevelt Resources.

Arcadia Biosciences and Roosevelt Resources have amended their Securities Exchange Agreement, extending the termination date to August 15, 2025, and modifying the share issuance terms for the all-stock transaction.

Mark Kawakami, CFO of Arcadia Biosciences, acquired 700 shares of common stock at $2.49 per share through the company's Employee Stock Purchase Plan (ESPP).

Arcadia Biosciences CEO Thomas Schaefer reports the purchase of 700 shares of common stock at $2.49 per share through the company's Employee Stock Purchase Plan.

Arcadia Biosciences will combine with Roosevelt Resources in an all-stock transaction, resulting in a shift of focus to oil and gas operations and a change of company name and ticker.

Arcadia Biosciences will combine with Roosevelt Resources in an all-stock transaction, marking a shift from agricultural innovation to oil and gas exploration and production.

Director Amy Yoder reports acquisition of stock options in Arcadia Biosciences.

Director Gregory D. Waller acquired stock options in Arcadia Biosciences, Inc. on August 19, 2024.

Lilian Shackelford Murray, a director of Arcadia Biosciences, acquired stock options exercisable for 10,909 shares of common stock on August 19, 2024.

Director Deborah Carosella acquired stock options in Arcadia Biosciences, Inc. on August 19, 2024.

Director Albert D. Bolles reports acquisition of stock options in Arcadia Biosciences.

Kevin Comcowich, a director at Arcadia Biosciences, acquired stock options for 25,455 shares on August 19, 2024.

Arcadia Biosciences' Chief Financial Officer, Mark Kawakami, reported the acquisition of stock options in the company.

Arcadia Biosciences CEO Thomas J. Schaefer reports the acquisition of stock options.

Mark Kawakami, CFO of Arcadia Biosciences, reports the acquisition of 700 shares of common stock through the company's Employee Stock Purchase Plan at a price of $2.06 per share.

Arcadia Biosciences CEO Thomas Schaefer purchased 700 shares of common stock at $2.06 per share through the company's Employee Stock Purchase Plan on August 1, 2024.